Glucagon
Also known as GlucaGen · rescue glucagon
Endogenous peptide hormone raising blood glucose; medical rescue drug and component of dual/triple agonist design.
How to picture it
Insulin's counterpart for raising blood sugar and mobilizing fuel — liver glycogen breakdown and gluconeogenesis when energy must come online. Also appears in dual/triple agonist drug design with GLP-1 for energy-expenditure signaling. Picture the "release fuel now" pager opposite insulin's store-and-use message.
Research focus & benefits
- Counter-regulatory glucose mobilization reference
- Energy-expenditure pathway interest in multi-agonists
- Foundational metabolic hormone biology
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
Glucagon counters insulin by raising blood glucose and is a standard rescue medication for severe hypoglycemia. It also features in next-gen obesity pharmacology (e.g., retatrutide glucagon receptor activity) for energy expenditure. Included for scientific completeness in metabolic peptide literacy.
Mechanism
Glucagon receptor activation in liver promotes glycogenolysis and gluconeogenesis; also affects satiety and energy expenditure pathways in drug design.
Research uses
- Hypoglycemia rescue (approved)
- Obesity multi-agonist design
- Diagnostic GI motility tests (historical)
Research dosing notes
Rescue products have clear emergency instructions. Not a fat-loss self-inject peptide.
Half-life / kinetics
Minutes
Common research routes
Reported considerations
- Nausea
- Vomiting
- Tachycardia
- Hyperglycemia
Contraindications / cautions
- Pheochromocytoma
- Insulinoma cautions
- Per product label
Common research stacks
- Always with glucose monitoring knowledge in insulin users
Legal / access note
Approved emergency and medical products exist; research misuse is inappropriate.